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1. Introduction 
On the one hand, probiotics as microbial cellular preparations of usefulness for human 
include a lot of examples of successful applications supporting healthy status of organism. 
Majority of probiotics are represented by lactobacilli, bifidobacteria, and their mixtures [1]. 
Among them Acilact (consortium Lactobacillus acidophilus NK1 + 100ash + K3III24), 
Lactobacterin (L. plantarum 8RA-3), Bifidin (Bifidobacterium adolescentis MC-42), 
Bifidumbacterin (B. bifidum N1), Biovestin (B. adolescentis + B. bifidum) and others are well-
known probiotics produced and used in Russia (Table 1). These probiotics are based on 
probiotic strains from healthy adults gut (Collection of microorganism at G.N. Gabrichevsky 
Research Institute for Epidemiology & Microbiology [2]). However being of live cell origin, 
survival and metabolism of probiotics could not be reliably controlled, and theoretically in 
some cases originally probiotic bacteria have some risk to be changed towards decreasing 
useful activities and revealing negative features similarly to some relative pathogens. So 
search of non-cellular types of natural agents imitating probiotics is really important. 
On the other hand, lectins as carbohydrate-binding/recognizing/sensitive proteins of non-
immunoglobulin nature are multifunctional and multidomain (at least one type domain is 
CRD: carbohydrate binding at the level of aminoacid sequence), widely occur in nature [3 - 
9], and can be specifically assembled to different soluble or not glycans, polysaccharides or 
glycoconjugates (GC) [glycoproteins, glycolipids, other glycol-non-proteins, any targets 
with exposed GC] in selected directions especially on solid or cell surfaces [10 - 15]. During 
assembling, lectin complexes: a) increase their multivalent and multifunctional recognition 
(more CBS: carbohydrate binding sites [CRD or epitopes in space], appearance of new types 
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of CBS and new targets are reached), b) form a dynamic partially reversible net system of 
lectin associates revealing carbohydrate recognition (the relatively changeable vector of 
resulting recognition by such a system can be evaluated by ordering a panel of carbohydrate 
targets according to their affinity to lectins). As a result, any lectin molecule in biological 
surroundings can be theoretically represented as: a) a lectin system (LS) of complexes and 
ensembles, b) a cascade of the directed assembling reactions, and c) a cascade system [16]. 
For example, complexes or oligomers of lectins or lectin-GC may be able to reveal new or 
modified carbohydrate/GC specificity, for example, in locations between subunits [14]. So 
lectin type cascades involving changeable originally the same molecules of lectins are 
possible.  
Lectins are represented by more than 20 families and large groups involving in regulation of 
metabolism and widely used in biotechnology [5, 7, 8, 13, 15, 17]. Symbiotic microbial lectins are 
important regulators of relationships between microbes and eukaryotic macroorganisms [16]. 
However, among symbiotic lectins, PBL are the least studied recognition factors [8, 16, 18].  
In 2004 probiotic bacterial lectins (PBL) including lactobacillar and bifidobacterial lectins (LL 
and BL) of human origin were firstly identified and preliminarily characterized by us [19]. 
The present study extend our knowledge concerning PBL as new class of natural symbiotic 
compounds. Such lectins may play important role in human superorganism in the 
regulation of inter- and intrapopulation relationships between bacteria and between bacteria 
and the host [20]. The data concerning lectins allow evaluation of important potential of PBL 
as cofunctioning factors produced by probiotics. The aim was to review our current study of 
PBL in aspects of their prospects for biotechnology and medicine. 
2. Isolation and characterization of PBL  
Criteria of choice of bacterial sources of PBL were:: a) probiotic lactobacilli and 
bifidobacteria, b) industrial strains, and c) consortium variants of increased antagonistic 
activities against reference microbial diagnosticums. Acilact corresponded to all these 
criteria. So LL isolated were represented as a combination of lectins of all ingredient strains 
of Acilact. Analogously, BL isolated included combination of lectins of strains MC-42 and 
N1. We studied lectins from probiotical lactobacilli and bifidobacteria, originally isolated 
from the healthy adults gut (Table 1). 
Identification of PBL [20] was performed using a panel of biotinylated artificial polymeric 
linear water-soluble GC (www.lectinity.com). Advantages of such GC were homogenecity, 
multiple carbohydrate residues in side exposed positions (on polyacrylamide chain) similar 
to mucin glycan clusters or to simple carbohydrate antigen organization, and increased 
affinity of interaction due to polyvalent carbohydrate targets. The combined scheme of 
identification and isolation of PBL is presented in Fig. 1. The critical step of identification is 
isoelectric focusing of protein fractions in the slab of polyacrylamide gel followed by gel 
electric blotting to membrane. Immobilized lectins treated with biotinyl-GC were visualized 
by streptavidin-peroxidase conjugate in the presence of chemiluminescent substrate of 
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peroxidase using Dark Room of the BioChemi System (UVP, Calif.). Chemiluminescence 
kinetics was registered to optimise regime of PBL registration. The main positions of PBL 
were established (see Table 2). Lectins revealed in acidic region (within pI 4-4.5) of pH 
gradient were combined as acidic PBL (preparations aLL and aBL), and lectins revealed in 
basic region (within pI 7.6-8) were combined as basic PBL (preparations bLL or bBL). 
Additional PBL were identified as slightly acidic (within pI 5.1-6) [21] or approximately 
neutral. Artificial Mannan [GC as polyMan]- or (Mucin-like[GC as polyGalNAc])-binding 
PBL were rerpresented by LL (preferentially Mucin-like binding) and BL (preferentially 
Mannan-like binding). Combined preparations of LL (aLL or bLL) of Acilact were 
represented by contributions of the corresponding aLL or bLL of Acilact ingredient strains. 
Similarly, combined LB of strains MC-42 and N1 completed each other.  
PBL were localized on the surface of bacteria (lactobacilli) within complexes which can be 
simply desorbed in the presence of LiCl (not NaCl). System of cell surface LL (as more 
protected) was represented by more extended panel of forms compared to secreted LL (as 
more dissociated and available to hydrolases of surrounding) into cultural fluid. Maximal 
forms of LL were obtained when boiled in the presence of sodium dodecyl sulfate (SDS) and 
2-mercaptoethanol (ME) (Table 3).  
2.1. Isolation of PBL  
Scheme of isolation of PBL is presented in Fig. 1. Being on the bacterial cell surface in 
complexes, PBL can be esially desorpted in vitro or in cultural fluids in the presence of 
chaotropic agents in combinations with surfactants (endogenic or exogenic) and chelate 
compounds. The way of isolation of active PBL is protected by the patent (in process). 
Procedure of PBL isolation needed approximately 3 days. As a result, PBL preparations 
were characterized as uncolor, transparent fluids, without smell, resistant to freezing.  
 
*Simultaneous identification of GC-binding PBL by blotting of a part of gel plate to membrane followed by membrane 
treating with GC-biotin and Streptavidin-Peroxidase.  
Figure 1.  Scheme of identification and isolation of PBL [5, 20].  
1. Growth of bacteria in fluid medium.  
2. Microfiltration and sterilization in Steriflip (Millipore).  
3. Concentration and concentrate washing in Centricon Plus-20 (Millipore). 
4. Precipitation of concentrate with ice acetone.  
5. Solubilization of precipitate in small volume. 
6. Isoelectric focusing in slab of polyacrylamide gel in the presence of urea and saccharose.  
7. Cutting out of lectins from the gel regions where acidic or basic PBL were identified*.  
8. Extraction of PBL from gel.  
9. Concentration and concentrate washing in phosphate buffer saline pH 7 (PBS). 
10. Freezing and storing aliquots of PBL. 
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No Species*, strains Previous names 
Probiotics in Russia including s 
train as ingredient 
1 L. helveticus NK1 L. acidophilus NK1 Acilact, Normospectrum, Polybacterin 
2 L. casei/paracasei  
                 K3III24 
L. acidophilus K3III24 Acilact, Normospectrum 
3 L. helveticus 100ash L. acidophilus 100ash Acilact 
4 L. plantarum 8RA-3 L. plantarum 8RA-3 Lactobacterin 
5 B. longum MC-42 B. adolescentis MC-42 Bifidin  
6 B. bifidum N1 B. bifidum N1 Bifidok, Bifidumbacterin  
*[46, 47]. 
Table 1. Probiotic lactobacillar and bifidobacterial strains (ingredients of probiotics) used in our work 
 
       General properties: 
 Original localization in ordered complexes within cell surface layers; facilitated 
desorption into surroundings  
 Molecular masses within 52-80 kD  
 System forms: acidic [a] (within pI 3.7-4.5), slowly acidic (within рI 5.1-6), neutral 
(within рI 6.5-7.5) and basic [b] (pI  7.6-8)  
 Contain exposed aromatic aminoacids: Tyr (partially masked in different erxtent in aLL 
and aBL), Trp (preferentially in BL, Phe (some differences between aLL and aBL)  
 Aggregation state (preferentially for aL)  
 Sensitivity to detergents (preferentially for bL)  
 Capability to adhesion on hydrophobic surfaces like polysterene and immobillon P (aL > bL) 
 Contain ions Ca, Mg 
Acidic LL: 
major 58-59 kD 
minors 60-62 and 53-55 kD 
рI 3.8-4 (2 bands) 
(D350 – D400)/D240= 46.3 
Acidic BL: 
Majors and minors 56-57, 53-54, 60-64 kD 
 
рI 3.7-4.2  (1 band + 2  dublet bands) 
(D350 – D400)/D240 = 66.7 
Basic LL: 
62-80 kD , рI  7.6-8 
(D350 – D400)/D240 = 33.8 
Basic BL: 
58-62; 52-54 kD;  рI 7.6-8 
(D350 – D400)/D240 = 33.2 
D= optical density. 
Table 2. Physicochemical and biochemical properties of PBL [5, 20, 22]   
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Sources of PBL Specificity to 
polymeric GC 
Positions of PBL 
bands, pI* 
Intensity of 
PBL** 
Protein concentrates    
В. adolescentis MC-42 GalNAc- 
Man(6-P)- 
Gal(3-Sulfate)- 
7.5-8 
6; 8 
4-5; 7 
4+/3+ 
3+/+ 
4+/+ 
В. gallinarum GB*** GalNAc- 
Man(6-P)- 
Gal(3-Sulfate)- 
8 
6.5; 7.5-8 
7 
2+ 
2+/+/3+ 
2+ 
В. bifidum N1 GalNAc- 
Man(6-P)- 
Gal(3-Sulfate)- 
7-7.5 
8 
4-5 
2+ 
2+ 
4+ 
LiCl-cell surface 
extracted protein 
concentrates 
   
L. acidophilus 100ash GalNAc- 
Man(6-P)- 
Gal(3-Sulfate)- 
5.1-7-7.5;8 
6.5 
5; 7 
+/4+/3+ 
2+ 
+/3+ 
L. acidophilus NK1 GalNAc- 
Man(6-P)- 
8 
6;6.5;7 
2+ 
+/2+/+ 
(SDS+МE)-treated 
proteins of concentrate 
fractions 
   
Acilact GalNAc- 
Man(6-P)- 
4.5-5.5;5.8;6.3 
5.5-6.5 
3+/3+2+ 
2+/3+/2+ 
L. acidophilus 100ash GalNAc- 
Man(6-P)- 
Gal(3-Sulfate)- 
5.8;6.2 
6-7 
5; 7 
+/+ 
2+/+ 
+/3+ 
L. acidophilus NK1 GalNAc- 
Man(6-P)- 
4.5-5;5.7;6.2 
5;6-6.8;7-8 
3+/2+/+ 
2+/2+/4+ 
*Isoelectric points (pI) according to isoelectric focusing in PAA gel in gradient of pH 4 - 8; ** in scale “+” - “4+” (relative 
chemiluminescence of complex PBL-b—Streptavidin-Peroxidase in the presence of chemiluminescent substrate of 
peroxidase). *** strain from chicken gut. SDS: sodium dodecyl sulfate, ME: 2-mercaptoethanol.  
Table 3. Identified PBL of different types [20].  
The main physicochemical and biochemical properties of PBL are presented in Table 2. As it 
can be seen from the Table 2, PBL are relatively hydrophobic proteins and can be presented 
in aggregated forms with partially exposed aromatic aminoacid residues (especially 
controlled for Tyr and Trp). Protein stability of PBL needed the presence of cocktail of 
protease inhibitors (“Complete”, R & D). Increased disappearance of bBL upon storing in 
glass tubes (compared to polypropylene tubes) for a long time was observed (increased 
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forms of PBL of L. helveticus NK1 (strain as dominated contributors of LL into Acilact) 
contain approximately 2 Ca2+ in molecule. Fluorescent properties of PBL (especially in case 
of BL) are increased in PBL complexes including endogenic exopolymers.  
Aforementioned data allow preliminary classifications of PBL [5, 7, 16]. Currently, PBL can 
be considered as: originally surface proteins of recognition, Ca2+ (and other metal cation)-
containing and binding proteins, relatively (random structure)-organized (decreasing of 
randomly ordered structure in complexes as refolding recognition process), preferentially 
originally mono- or bivalent (one CBS in polypeptide) low sensitive haemagglutinins 
(similar to pan-agglutinins), with capability to create complexes, oligomeres and aggregated 
particles, members of functional superfamilies. 
2.2. Biological properties of PBL 
PBL imitate the following general main activities of probiotics: antimicrobial, 
immunocorrecting, ssupporting consortium, stabilizing healthy status in communicative 
directions “Microbes - Microbes” and “Microbes - Host”. In addition, PBL reveal unique 
properties which complete probiotics to synbiotics and extend spectrum of useful activities 
in combinations “Probiotics + PBL” (see below).  
PBL are represented by four LS (Table 1). Among them LL and LB (acidic and basic) were 
isolated and studied by us in detail. In addition, in case of slowly acidic LL it was suggested 
their potential cofunctioning to oxidase-reductase system within potential lactobacillus 
consortium of Acilact strains and L. plantarum 8RA-3 [21]. The role of such LL may be in 
regulation of protection of probiotic consortium in biotopes against peroxide stress. 
Examples of regulation of oxidoreductases with lectins are well documented [15]. Mean 
time, the role of neutral LL is still unclear.  
2.2.1. Interactions between PBL and GC [14, 17, 19, 20, 22-24]  
Major forms of soluble PBL are represented mainly as molecules and their complexes with 
one CBS. Such PBL forms needed hydrolase treated red cells for visualization of 
haemagglutination reaction. In haemagglutination reaction (Clostridium perfringens sialidase-
treated human AII-blood group erythrocytes) interaction between PBL and GC was as 
approximately equimolar (1 : 1, M/M).  
We identified different lectins secreted by lactobacilli and bifidobacteria using a panel of GC 
and mainly three methods including: a) dot-blotted supernatant concentrates on 
Immobillon-P membrane (Millipore), b) proteins blotted after isoelectric focusing 
supernatant concentrated protein fractions in polyacrylamide plate, c) proteins sorpted on 
sialidase (or trypsin)-treated human AII-red cells [5, 22 - 25].  
For identification of lectins among extended panel of lactobacilli and bifidobacteria strains 
we used GC (0.5-5 mkg/ml, PBS) containing multiply exposed side carbohydrate residues on 
biotynylated (b) or not polyacrylamide (PAA) chain (www.lectinity.com):  
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 Fucα1- [α-L-Fucan-like], 
 Galβ1- [β-D-Galactan-like], 
 Gal(3-Sulfate)β1- [3-HSO3Galβ1- ;β-D-Galactan-3-Sulfate polymer], 
 GaNAcα1- [Tn-like antigen containing polymer], 
 GalNAcα1,3Galβ1- [Adi as (AII-blood group substance)-like containing polymer], 
 GalNAcα1,3GalNAcβ1- [Fs as (Forssman antigen)-like containing polymer], 
 GalNAcα1,3GalNAcα1- , 
 Galα1,3GalNAcα1- [Tαα-like antigen containing polymer], 
 GalNAcβ1- [desialylated Mucin-like], 
 Galβ1,4GlcNAcβ1- [poly(LacNAc)-containing mucin-like], 
 GlcNAcβ1- [soluble linear Chitin-like], 
 Manα1- [α-D-Mannan-like], 
 Man(6-phosphate)α1- [6-H2PO3Manα1-polymer; α-D-PhosphoMannan], 
 (MurNAc-L-Ala-D-isoGln)β1- [MDP-; Muramyldipeptide containing polymer; bacterial 
Peptidoglycan-like], 
 Rhaα1- [α-L-Rhamnan-like]. 
The whole resulted chemiluminescent pictures of LL and BL separated by isoelectric 
focusing followed by blotting were distinct and needed individual optimized regimes of 
registration. It is seen from the Table 3 that: a) the pictures of PBL are unigue and depended 
on strain origin, b) dominated PBL types are revealed as mucin- and/or Mannan-binding; b) 
PBL of probiotic consortium include PBL of ingredient strains. Mannan-binding lectins of L. 
plantarum 8RA-3 possessed increased intensities of chemiluminescence [19]. These data were 
supported by study of PBL specificity to GC in haemagglutination reaction [5, 23]. 
Dissociation of PBL-(hydrolase-treated human AII-red cells) agglutinates was observed in 
the presence of 0.5-1 mkg/ml of GC. Effectivenes of GC was decreased in the order: 
poly(GalNAc) or Mannan > Galactan >> Chitin-like polymer (no influence).  
In other seria of experiments we extended panel of probiotic bacteria and extended panel of 
GC to identify new PBL types using dot-blotting technique [24, 25]. It was shown that PBL 
of lactobacilli and bifidobacteria are capable to discriminate GalNAc-containing GC 
(GalNAc residues as exposed, internal/masked, or dublicated) glycoantigens Adi-, Fs-, or Tn- 
depending on strain origin. No binding of PBL to Tαα was observed. PBL also discriminated 
artificial peptidoglycan, mannans and mucins. Due to PBL revealing as LS [16] when two or 
more PBL forms (major and minor ones) vary on specificity, similarity (identical part of 
mosaic of the same specificity) and differences (the whole mosaic as unique, ranging 
intensity of components with the same specificity, some components which simultaneously 
recognize two types of target GC) between recognizing potential of species and genus of 
lactobacilli and bifidobacteria can be established. 
Using dot-blotting technique, at least 7 types of LS were identified for extended panel of 
lactobacilli and bifidobacteria which occur in human gut. Among these, LS were 
represented by lectins which especially significantly recognized α–D-Mannan 
(phosphorylated or not; yeast-like), α-L-Fucan (algal-like), peptidoglycan (bacterial-like), 
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mucins (mammalian gut-like); antigens Тn and Forssman, blood group AII substance. Such 
lectins were identified as mosaic within bacterial mainly acidic protein massive.  
Aforementioned data on interaction between PBL and GC indicate that PBL may serve as 
additional important functional characteristic. The latter can serve the basis to study biotope 
metabolic relationships involving probiotic bacteria as antagonistic to opportunistic 
microorganisms in keeping healthy biotope status; and to construct cofunctioning systems 
of PBL together with yeast and higher plant ingredients.  
Antimicrobial activities of PBL against clinical microbial strains [21, 26-32] included: 
- Growth inhibition; 
- Involving biodegradation (proteolysis) (LL > BL);  
- Synergistic action (LL + BL: against staphylococci [effectiveness: LL > BL]; BL + LL: 
against microfungi [effectiveness: BL > LL]; BL + antibiotics: against Candida species 
[possibility to decrease effective work doses of antibiotics]);  
- Action as cascades (action of aPBL followed by action of bPBL); 
- Concurent use of resources of pathogens during their different live cycle steps (wrong 
essembling of biofilms of pathogens, choice and switching of metabolome nets, 
increased degradation of pathogen constructions including their lysis). 
The following general comments on antimicrobial action of PBL should be noted. The action 
of PBL is directed against colorectal and urogenital clinical strains from human biotopes. 
PBL act as the members of new class of biofilm destructors [27]. Anti-Staphylococcus and 
anti-Candida action reveal multistep synergism in space (different regions of action of aLL 
and bLL, aBL and bBL, aLL and aBL, antibiotic-like and lytic actions) and in time (earlier 
action as antibiotic-like, later lytic action of aPBL followed by lysis by bPBL). It takes place 
multisynergism of anti-Candida action between PBL and antibiotics (azoles, amphotericin B, 
nystatin). Taken together, PBL imitate anti-Staphylococcus and anti-Candida activities of 
probiotic lactobacilli and bifidobacteria [33, 34] and can be potentially used for treatment of 
candidoses and staphylococcoses. 
It should be also noted that PBL possess advantages compared to other antimicrobials: 
prolonged action; cascade synergistic action, low subcytoagglutinating doses; non-
dependence on antibiotic types (upon therapy) [probiotics delivered can be inactivated by 
some antibiotics]. In addition, ketokonazol and some other antibiotics are poorly soluble in 
PBS that decreases their effectiveness and control. 
2.2.2. Activities of PBL in respect of potential probiotic compartment of biotope [35, 37, 38] 
PBL reveal a spectrum of activities in respect of populations of lactobacilli isolated from the 
same biotope. Results indicate that LL support healthy status of normoflora in biotope due 
to realization of supervisor signal functions of PBL. It is expected that when delivered, PBL 
increase synbiotic compartment of biotope against potential pathogenic compartment (in 
addition to other positive events in  direction “Microbiocenoses - Host”).  
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2.2.3. Other biological activities of PBL 
Activities of PBL in respect of cells of mammalian protection systems [22, 27]: 
- Inducing production of TNF-α by human periphery blood lymphocytes; 
- Modulation of peritoneal macrophage migration in manner which is differed from 
action of GC; 
Predicted PBL activities based on similarities to symbiotic bacterial lectins [16], other lectins 
and probiotics:  
- As possible ingredients of drug forms in cases of colorectal alterations (potential 
effectiveness: BL > LL), or urogenital alterations (potential effectiveness: LL > BL). 
- Direct antitumor action: against changed human cell systems similarly to PBL action 
against eukaryotic pathogens as xenoagents in organism (potential effectiveness: BL > 
LL); througph increased affinity of PBL to Poly(LacNac) as potential tumor antigens 
[14] (potential effectiveness: LL > BL); 
- Against protozoan pathogens (like action against another type of eukaryotic pathogens 
- microfungi); 
- Against viruses (like Acilact action against rotavirus infection of children; similar to 
Mannan-binding phytolectins possessing activity against HIV-1); 
- Intracellular sorting into organells and vesicules [due to capability of PBL to recognize 
poly(Man-6-P) within targets, similar to animal Man-6-P-binding lectins)]; 
- Biocompatibility and synergism of LL and/or BL together with other probiotic microbial 
lectins as antimicrobials; 
- Biocompatibility and synergism of PBL to other type antimicrobials possessing distinct 
mechanisms of action;  
- The possible forming additional antimicrobial pool as PBL fragments in the presence of 
host and microbial hydrolases of surroundings in biotopes. 
3. Conclusion 
All aforementioned data support wide potential of PBL for industrial and medical 
biotechnology.  
The following main prospects of applications of PBL can be underlined: 
For cell cultures [autostimulators, supporting probiotic bacterial cultures: mixed or not, in 
the presence of pathogen, etc.],  
In constructing bioadditives, anti-infectives and drug forms [system drugs of synergistic 
and selective action as antipathogenic agents, and as factors supporting probiotic 
compartment in biotopes];  
In diagnostics [microassays; for typing clinical pathogen strains; for detecting altered 
anormal surface and metabolome net of pathogenic significance] [28, 29, 32],  
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In constructing of cascade biosensors based on LS-organization of PBL [for monitoring 
biotope healthy balance, for screening strains and their mixtures especially on solid surfaces 
like sensibilized membranes, polysterol or polypropelene;  
In constructing predictable lactobacilli- and bifidobacteria-based consortia as potentially 
probiotics-like, constructing synbiotic consortia [37, 38]: 
- keeping metabolome status; 
- switching (on/off) microbial nets and cascades;  
- controlling microbiocenosis functioning; providing cell teaching; 
- factors in constructing of beneficial microbiocenoses; 
- directed antipathogen action by changing ontogenesis of pathogens) [27]; 
- helpers in building cell and cytokine-like gradients [23];  
- synergistic and synbiotic factors in mixed cultures of microorganisms or in host 
biotopes [32];  
- stabilizers of poorly growth probiotic microorganisms [35, 36];  
- co-functioning with other PBL-like and non-PBL antimicrobials produced by probiotic 
compartment of biotope (bacteriocins, antimicrobial peptides and biosurfactants) [22, 39] 
- co-functioning with human cytokines (PBL as cytokine inducers), defensins, antibiotics 
(synergism), antibodies [9, 39, 40];  
- synergism of PBL signaling and signal proteinases/oligopeptidases and (oligo)peptides 
of surrounding; 
- screening, selection and typing of strains; 
- ingredients of both free cell drug ointments and cosmetic creams (improving formulas) 
[39, 41];  
- in recombinant lectin technologies [17]; 
- carriers for drug delivery, carriers of low molecular weight highly hydrophobic 
heterocyclic effectors (some antibiotics, chemotherapeutic antitumor agents, apoptose 
inducers, etc.) [3, 17];  
- ingredients of functional bioadditives [41]; 
Upon chemotherapy and radiotherapy of tumors to support healthy status of organism [36, 42] 
In system drug therapy when added PBL (LL and/or BL) will modulate whole spectrum of 
system drug activities;  
In landscape microecology and architectuire of microbiocenoses (PBL as the direct 
participants and organizers of landscapes) [32]. 
It is clear that solid or cell surfaces are of preferential importance for any directed 
assembling initiated by PBL (increased accumulated interphased concentrations of reactants, 
initiating or triggering assembling on immobilized first components of cascades, 
achievement of maximally long and asymmetric products). That is why PBL within  
pore PAA hydrophilic gels or membranes (Durapore membranes as [multi]layer 
microaccumulators), immobilized PBL on PVDF membranes (Immobillon P) or polysterene 
microplates and latex particles are of especial perspectiveness.  
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Appendix 
List of abbreviations 
a – acidic 
b – basic 
CBD – carbohydrate binding domain 
CBS – carbohydrate binding site 
D – optical density 
BL       bifidobacterial lectins 
LL      lactobacillar lectins 
LS      lectin system(s) 
PBL – probiotic bacterial lectins 
GC – glycoconjugate(s) 
PBS – phosphate buffer saline pH 7 
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